Psychiatric Medication Classes: Reference Guide for Patients and Providers

Psychiatric medications span more than a dozen distinct pharmacological classes, each targeting different neurotransmitter systems and approved for different diagnostic indications. This reference covers the major categories — antidepressants, antipsychotics, mood stabilizers, anxiolytics, stimulants, and more — explaining how each class works, when it's used, and how clinicians weigh one option against another. The goal is to give patients and providers a shared vocabulary for conversations that often happen under pressure, in limited time, with high stakes.

Definition and scope

A psychiatric medication is any pharmacological agent prescribed primarily to alter mood, cognition, perception, or behavior through action on the central nervous system. The FDA has approved more than 30 individual agents in the antidepressant category alone, with hundreds more across the full psychiatric formulary.

The six major classes in routine clinical practice are:

1. Antidepressants — including SSRIs, SNRIs, TCAs, and MAOIs
2. Antipsychotics — first-generation ("typical") and second-generation ("atypical")
3. Mood stabilizers — lithium and certain anticonvulsants
4. Anxiolytics and sedative-hypnotics — benzodiazepines, buspirone, and non-benzodiazepine sleep aids
5. Stimulants and non-stimulant ADHD agents — amphetamines, methylphenidate, atomoxetine, viloxazine
6. Emerging and adjunctive agents — ketamine/esketamine, naltrexone, prazosin, and others used off-label or for co-occurring conditions

Each class is discussed in greater depth on the medication for mental health reference page, which addresses dosing principles, monitoring requirements, and black-box warning summaries.

How it works

The dominant model for psychiatric pharmacotherapy holds that these medications modulate neurotransmitter availability, receptor sensitivity, or signal transduction pathways. In practice, the mechanism varies substantially by class.

SSRIs and SNRIs block reuptake of serotonin (SSRIs) or serotonin and norepinephrine (SNRIs) at the presynaptic membrane, increasing the concentration available in the synaptic cleft. Fluoxetine, sertraline, escitalopram, and venlafaxine are among the most prescribed agents in this group. They are first-line for depression and mood disorders, anxiety disorders, PTSD and trauma-related disorders, and obsessive-compulsive disorder.

Tricyclic antidepressants (TCAs) and MAOIs predate SSRIs and carry more complex side-effect profiles. TCAs block reuptake of both serotonin and norepinephrine but also act on histamine and acetylcholine receptors, producing sedation and anticholinergic effects. MAOIs inhibit the enzyme monoamine oxidase, preventing breakdown of serotonin, dopamine, and norepinephrine — but require dietary tyramine restriction to avoid hypertensive crisis.

First-generation antipsychotics (haloperidol, chlorpromazine) act primarily as D2 dopamine receptor antagonists. Their efficacy in psychosis is well established, but the risk of tardive dyskinesia — a movement disorder that can be irreversible — limits long-term use. Second-generation antipsychotics (olanzapine, quetiapine, aripiprazole, risperidone) add serotonin receptor antagonism to the profile, which appears to reduce extrapyramidal side effects while introducing metabolic risks including weight gain and elevated blood glucose. Both generations are central to treatment of schizophrenia and psychotic disorders and are used adjunctively in bipolar disorder.

Lithium, the original mood stabilizer and still a benchmark agent, works through mechanisms that remain incompletely understood — likely involving glycogen synthase kinase-3 (GSK-3) inhibition, inositol depletion, and neuroprotective effects. Therapeutic serum levels fall in a narrow range (0.6–1.2 mEq/L for maintenance), making routine blood monitoring non-negotiable.

Benzodiazepines potentiate GABA-A receptor activity, producing rapid anxiolytic and sedative effects. Their speed is a clinical asset in acute settings; their tolerance and dependence potential is a liability in long-term use. The addiction and co-occurring disorders context makes careful prescribing especially consequential.

Common scenarios

Psychiatric medication is rarely a single-agent, single-diagnosis situation. Three patterns appear with particular frequency:

Treatment-resistant depression is formally defined as failure to respond to at least 2 adequate antidepressant trials. In this scenario, clinicians may add an atypical antipsychotic as augmentation, switch to an SNRI or bupropion, or consider referral for electroconvulsive therapy and brain stimulation. The FDA approved esketamine (Spravato) in 2019 specifically for treatment-resistant depression, administered intranasally under clinical supervision.

Bipolar disorder requires particular caution with antidepressant monotherapy, which can precipitate manic episodes in some patients. Mood stabilizers — lithium, valproate, lamotrigine — form the pharmacological backbone, often combined with an atypical antipsychotic during acute episodes.

ADHD in adults is addressed with Schedule II stimulants (amphetamine salts, methylphenidate) as first-line options, or non-stimulant alternatives (atomoxetine, viloxazine, guanfacine) when stimulants are contraindicated due to cardiovascular history, active substance use disorder, or patient preference. See the ADHD and neurodevelopmental disorders section for a fuller breakdown.

Decision boundaries

Choosing among agents within a class — or between classes — involves weighing five intersecting factors:

• Diagnostic indication: Some agents carry FDA approval for specific diagnoses; off-label use requires documented clinical rationale.
• Side-effect tolerability: A medication that disrupts sleep, causes sexual dysfunction, or produces significant weight change may be discontinued regardless of efficacy.
• Drug-drug interactions: Polypharmacy is common in psychiatric populations. CYP450 enzyme interactions, particularly with fluvoxamine, fluoxetine, and bupropion as inhibitors, can elevate or reduce serum levels of co-administered medications.
• Patient history and genetics: Pharmacogenomic testing (e.g., for CYP2D6 and CYP2C19 variants) can inform dose selection, though the American Psychiatric Association notes that clinical evidence for routine testing remains under active evaluation.
• Monitoring burden: Lithium, clozapine, and valproate each require specific laboratory monitoring schedules that affect adherence and access.

The contrast between first- and second-generation antipsychotics illustrates how these boundaries play out: older agents often carry lower metabolic risk but higher neurological risk; newer agents invert that trade-off. Neither class is categorically superior — the decision is patient-specific, built from history, comorbidities, and what the patient is willing to sustain.

Medication is one component of care. Psychotherapy types and approaches and structured supports often work in parallel, and the evidence base for combined treatment exceeds the evidence for either modality alone in most diagnostic categories.